ACTRN12614000873628已完成2 期
A pilot randomised controlled trial of omega-3 fatty acid supplements to prevent skin cancer in lung transplant recipients
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Prevention
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1.Male and female lung transplant recipients Greater than or equal to 18 years of age.
- •2.Greater than or equal to 1 year post lung transplant.
- •3.Use of systemic retinoid therapy permitted if on stable dosing for previous 3 months.
- •4.Will be able to attend the clinic for at least Visit 1 and Visit 4 within the recruitment timeframe.
排除标准
- •1. Unable to give informed consent.
- •2. Have innately black or dark brown skin.
- •3. Have a fish allergy.
- •4. Have a soya allergy.
- •5. Unable to take gelatin.
- •6. Have a bleeding disorder or bleeding episode in last 3 months
- •7. Are receiving warfarin, heparin or low molecular weight heparin in therapeutic doses. (Patients receiving heparin or low molecular weight heparin in prophylactic doses will not be excluded)
- •8. Are already taking fish oil supplements and unwilling to discontinue for 2 months before randomisation and for trial period.
- •9. Pregnant
研究者
相似试验
已完成
2 期
Evaluation of omega-3 in reduction of myocardal damage in patients with myocardial infarctions who undergoing streptokinase therapyMyocardial Infarction.I23-I25.8Myocardial InfarctionIRCT201402078307N5Vice chancellor for research of Tabriz University of Medical Sciences.100
进行中（未招募）
不适用
A phase III, observer-blind, randomised trial to evaluate the safety and immunogenicity of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvanted or not with AS03A in adults aged 18 to 60 years. - FLU D-PAN H1N1-AS03-033EUCTR2009-016078-33-BEGlaxoSmithKline Biologicals128
进行中（未招募）
1 期
Phase III randomised, placebo controlled study of sorafenib in repeated cycles of 21 days in combination with paclitaxel/carboplatin chemotherapy in subjects with unresectable stage III or stage IV melanomaEUCTR2005-000941-12-GBOnyx Pharmaceuticals, Inc.
已完成
不适用
A phase III open, randomised, controlled study to evaluate the safety and immunogenicity of a paediatric dose (0.25 ml) and the standard dose (0.5 ml) of Epaxal® with reference to comparator vaccine in healthy children and adolescents (12 months to 16 years of age inclusive), using a 0/6 month scheduleHepatitis A VirusInfections and InfestationsHepatitisISRCTN91009479Berna Biotech AG (Switzerland)360
进行中（未招募）
不适用
A Phase III randomised, controlled trial of exercise during chemotherapy for patients commencing first line treatment for ovarian cancerCancer - Ovarian and primary peritonealOvarian CancerACTRN12614001311640niversity of Sydney524